Navigation Links
Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
Date:8/19/2007

Pharmatek Now Offers Contract Cytotoxic & High-Potent Analytical,

Formulation and Manufacturing Services

SAN DIEGO, Aug. 16 /PRNewswire/ -- Pharmatek Laboratories, Inc. today announced the addition of cytotoxic and high-potent drug development capabilities to its pharmaceutical chemistry development services. Cytotoxic and high-potent services include analytical method development, preformulation testing, formulation development, manufacturing for early phase clinical trials, release testing, and stability testing and storage.

"This expansion was driven by an increase in demand for cytotoxic and high-potent drug development and manufacturing outsourcing among our clients," said Dr. Jeffrey Bibbs, CEO of Pharmatek. "This added capability enables us to provide a broader level of services to our clients with cytotoxic and high-potent candidates."

Pharmatek's cytotoxic and high-potent development services will be carried out in a separate dedicated facility. Manufacturing capability includes two validated and licensed class 100,000 high-containment suites designed with barrier technology for cGMP manufacturing of final form drug products. Dedicated HVAC and HEPA filtration systems ensure product containment within the suites. Personnel are protected through strict gowning and control procedures to ensure employee safety while working in the suites.

"Pharmatek has been a valued resource for the development and manufacturing of non-potent drugs for more than eight years," said Timothy Scott, president of Pharmatek. "This investment positions Pharmatek to become a leading cytotoxic and high-potent drug development service provider."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discov
'/>"/>

SOURCE Pharmatek Laboratories, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43)
2. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
3. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
4. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
5. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
6. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
7. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
8. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
9. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
10. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
11. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ... the beginning of a long-term relationship with Veterinary ... behalf of its members to provide access to ... extremely pleased to count VGP as a dedicated ... arthritic dog patients nationwide. Concentrating and using stem ...
(Date:5/26/2015)... 26, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that all outstanding common share ... prior to their expiry on June 15, 2015, resulting ... "We thank our shareholders for their continued ... of Asterias. "This exercise of warrants represents a strong ...
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/26/2015)... May 26, 2015 Just the characterization ... long-standing unmet biomedical need does not guarantee immediate acceptance. ... that has seen many prior failures is often met ... and use is an irony that is often an ... new start-up company, Asymmetrex has found that ...
Breaking Biology Technology:VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
... 22 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... the recently disclosed temporary suspension,of NASDAQ,s minimum bid closing ... the Company now has until March 20, 2009 to ... a closing bid price of $1.00 or more for ...
... NicOx,S.A. (Euronext Paris: COX) today reported financial results for the nine,months ... quarter of 2008:, - Positive top-line results from the 302 ... co-primary efficacy endpoints at week-13 (p naproxcinod 750 ... non-inferiority to naproxen 500 mg bid at week-13 and 26. ...
... to Show Encouraging and Durable Anti-Tumor Activity and ... Dose Escalation Continues -, - Results Presented at ... Targets and ... MDVN ) today announced the presentation of new data from an,ongoing Phase ...
Cached Biology Technology:NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009 2NicOx Reports Results for the First Three Quarters of 2008 2NicOx Reports Results for the First Three Quarters of 2008 3NicOx Reports Results for the First Three Quarters of 2008 4NicOx Reports Results for the First Three Quarters of 2008 5NicOx Reports Results for the First Three Quarters of 2008 6NicOx Reports Results for the First Three Quarters of 2008 7NicOx Reports Results for the First Three Quarters of 2008 8NicOx Reports Results for the First Three Quarters of 2008 9NicOx Reports Results for the First Three Quarters of 2008 10Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4
(Date:5/19/2015)... May 19, 2015  Technology is rapidly advancing, outpacing ... in the cloud. Passwords and their management are soon ... and standards-based specifications such as those developed by the ... of passwords presents for BYOD, COPE, IoT, and mobile ... identity protocol. In response to the ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... the performance of different types of green roofs has ... at The University of Texas at Austin and suggests ... Interest in vegetated roofs has increased as water ... Yet the study of six different manufacturers, products found ...
... Elephant seals are helping scientists overcome a critical blind-spot ... circulation and sea ice production and its influence on ... a team of French, Australian, US and British scientists ... Sciences, elephant seals fitted with special oceanographic sensors ...
... A new book written by University of California, ... of intellectual property protection for plants over the ... to ensure that plant genetic resources remain freely ... and researchers. "Seed Wars: Controversies and Cases ...
Cached Biology News:Green roofs differ in building cooling, water handling capabilities 2Green roofs differ in building cooling, water handling capabilities 3Southern Ocean seals dive deep for climate data 2
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: